申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US04469865A1
公开(公告)日:1984-09-04
1,3-Disubstituted imidazoles of the general formula (I): ##STR1## wherein A and B may be the same or different, and each is a straight- or branched-chain alkylene or alkenylene group having 1 to 8 carbon atoms, Y is an acyl group having 2 to 10 carbon atoms, an alkoxycarbonyl group having 2 to 7 carbon atoms or an dialkoxymethyl group having 3 to 13 carbon atoms, Z is a cyano group or an alkoxycarbonyl group having 2 to 7 carbon atoms, X is a halogen atom, n is zero or 1. The said compounds are intermediates for producing the imidazole derivatives of the general formula (V) above which possess strong and specific inhibitory effects on thromboxane synthetase and thus are useful as therapeutical agents for treatment of diseases caused by thromboxane A.sub.2.
通用公式(I)的1,3-二取代咪唑化合物如下:其中A和B可以相同也可以不同,每个都是具有1至8个碳原子的直链或支链烷基或烯基基团,Y是具有2至10个碳原子的酰基基团,具有2至7个碳原子的烷氧羰基基团或具有3至13个碳原子的二烷氧甲基基团,Z是氰基或具有2至7个碳原子的烷氧羰基基团,X是卤素原子,n为零或1。所述化合物是制备通用公式(V)的咪唑衍生物的中间体,这些咪唑衍生物对血栓素合成酶具有强烈和特异的抑制作用,因此可用作治疗由血栓素A.sub.2引起的疾病的治疗剂。